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ανβ3Pleiotrophin (PTN) is a heparin-binding growth factor that induces cell migration through binding to its receptor
protein tyrosine phosphatase beta/zeta (RPTPβ/ζ) and integrin alpha v beta 3 (ανβ3). In the present work, we
studied the effect of PTN on the generation of reactive oxygen species (ROS) in human endothelial cells and
the involvement of ROS in PTN-induced cell migration. Exogenous PTN signiﬁcantly increased ROS levels in a
concentration and time-dependent manner in both human endothelial and prostate cancer cells, while
knockdown of endogenous PTN expression in prostate cancer cells signiﬁcantly down-regulated ROS production.
Suppression of RPTPβ/ζ through genetic and pharmacological approaches, or inhibition of c-src kinase activity
abolished PTN-induced ROS generation. A synthetic peptide that blocks PTN–ανβ3 interaction abolished PTN-
induced ROS generation, suggesting that ανβ3 is also involved. The latter was conﬁrmed in CHO cells that do
not express β3 or over-express wild-type β3 or mutant β3Y773F/Y785F. PTN increased ROS generation in cells
expressing wild-type β3 but not in cells not expressing or expressing mutant β3. Phosphoinositide 3-kinase
(PI3K) or Erk1/2 inhibition suppressed PTN-induced ROS production, suggesting that ROS production lays
down-stream of PI3K or Erk1/2 activation by PTN. Finally, ROS scavenging and xanthine oxidase inhibition
completely abolished both PTN-induced ROS generation and cell migration, while NADPH oxidase inhibition
had no effect. Collectively, these data suggest that xanthine oxidase-mediated ROS production is required for
PTN-induced cell migration through the cell membrane functional complex of ανβ3 and RPTPβ/ζ and activation
of c-src, PI3K and ERK1/2 kinases.
© 2015 Elsevier Inc. All rights reserved.Introduction
Pleiotrophin (PTN) is a heparin binding growth factor with a
signiﬁcant regulatory role on inﬂammation, angiogenesis and cancer
(Pantazaka and Papadimitriou, 2012; Papadimitriou et al., 2009; Silver
et al., 2012; Yokoi et al., 2012; Zhang et al., 2013). In all cases, the best
characterized PTN function is its effect on cell migration through its
receptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ) (Lu et al.,
2005; Polykratis et al., 2005) and integrin alpha v beta 3 (ανβ3)
(Mikelis et al., 2009). Part of the downstream signaling has been
elucidated and involves c-Src kinase, phosphoinositide 3-kinase (PI3K)
and ERK1/2 activation (Koutsioumpa et al., 2013; Mikelis et al., 2009;
Polykratis et al., 2005). However, a lot of work is still required in order
to uncover more players, as well as to pinpoint how all these players
communicate to regulate the effect of PTN on cell migration..
sion of DigestiveDiseases, David
geles, Los Angeles, CA, USA.Reactive oxygen species (ROS), like hydrogen peroxide, superoxide
and the hydroxyl radical, are constantly produced during normal
metabolism and in response to external stimuli. At higher concentra-
tions following oxidative stress situations, ROS may damage proteins,
lipids and DNA, andmay induce apoptosis. In contrast, after stimulation
by various external factors, including growth factors, hormones and
cytokines, or cellular events such as adhesion, cells will produce low
local amounts of ROS (Dhar-Mascareno et al., 2003; Hatziapostolou
et al., 2006; Terman et al., 1992),which have been identiﬁed as essential
mediators that regulate the transduction of signals from the membrane
to the nucleus via oxidation and reduction in proteins (Holmström and
Finkel, 2014) and lead to angiogenesis stimulation (Kim and Byzova,
2014; Polytarchou and Papadimitriou, 2004, 2005, Polytarchou et al.,
2009) and inﬂammation linked to several pathologies (Bryan et al.,
2012; Naik and Dixit, 2011). ROS are produced by a number of path-
ways, including themitochondrial electron transport chain, cytochrome
P450, xanthine oxidase (XO), uncoupled nitric oxide synthase and the
family of NADPH oxidase enzymes (Bir et al., 2012; Wilkinson-Berka
et al., 2013).
The aim of the present study was to investigate whether PTN affects
ROS production by human endothelial and prostate cancer cells and
whether ROS production is involved in PTN-induced cell migration.
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Materials
Human recombinant PTN was from PeproTech, Inc. (Rocky Hill,
NJ, USA). The NAD(P)H oxidase-speciﬁc inhibitor 4-hydroxy-3-
methoxyacetophenone (apocynin) and the ROS-sensitive ﬂuores-
cent dye, 5(6)-carboxy-2,7-dichlorodihydroﬂuorescein diacetate
(carboxy-H2DCFDA) were purchased from Fluka. The hydrogen
peroxide scavenger catalase, the NAD(P)H oxidase inhibitors 4-(2-
aminoethyl)benzenesulfonylﬂuoride (AEBSF) and 3-benzyl-7-(2-
benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine (VAS2780), the XO
inhibitor allopurinol and the general phosphatase inhibitor sodium
orthovanadatewere purchased from Sigma. The XO inhibitor febuxostat
was from Santa Cruz Biotechnology, Inc. The mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase (MEK) inhibitor
U0126 and the src kinase inhibitor PP1 were purchased from
Tocris (Ellisville, MO, USA). RNA oligonucleotide primers for RPTPβ/ζ
(Polykratis et al., 2005) were obtained from VBCBiotech Services
(Vienna, Austria), and for human XO were obtained from Santa Cruz
Biotechnology, Inc. Double-stranded negative control siRNA was
from Ambion (Austin, TX, USA). B3 (CYDMKTTC) and B3 scrambled
(TKCMTCDY) peptides were from Cambridge Peptides (Birmingham,
UK). All the inhibitors and antioxidants at the concentrations used
were not toxic to the cells (data not shown).
Cell culture
Human umbilical vein endothelial cells (HUVEC), human glioma
M059K cells, Chinese hamster ovary (CHO) cells deﬁcient in endog-
enous β3 and human prostate cancer epithelial cell lines LNCaP and
PC3 were cultured as previously described (Hatziapostolou et al.,
2005; Koutsioumpa et al., 2013; Tsirmoula et al., 2012). Stable CHO
clones expressing wild-type β3 or mutant β3Y773F/Y785F were
generated as previously described (Mikelis et al., 2009). Cell culture
reagents were from BiochromKG (Berlin, Germany). All cultures
were maintained at 37 °C, 5% CO2 and 100% humidity. When cells
reached 80–90% conﬂuence, they were serum-starved for 16 h
before performing any further experiments.
Migration assay
Migration assays were performed as previously described
(Koutsioumpa et al., 2013) in 24-well microchemotaxis chambers
(Corning, Inc., Lowell, MA, USA) using uncoated polycarbonate
membranes with 8-μm pores. Serum-starved cells were harvested and
resuspended at a concentration of 105 cells/0.1 ml in serum-free
medium containing 0.25% bovine serum albumin (BSA). The bottom
chamber was ﬁlled with 0.6 ml of serum-free medium containing
0.25% BSA and the tested substances. The upper chamber was loaded
with 0.1 ml of medium containing the cells and incubated for 4 h at
37 °C. After completion of the incubation, the ﬁlters were ﬁxed and
stained with 0.33% toluidine blue solution. The cells that migrated
through the ﬁlter were quantiﬁed by counting the entire area of each
ﬁlter, using a grid and an Optech microscope (Optech Microscope
Services Ltd., Thame, UK) at an ×20 objective.
RNA interference
HUVECwere grown to 50% conﬂuence inmediumwithout antibiotics.
Transfectionwas performed in serum-freemedium for 4husing annealed
RNA for RPTPβ/ζ at the concentration of 50 nM and jetSI-ENDO (Polyplus
Transfection, Illkirch, France) as transfection reagent (Polykratis et al.,
2005), or XO at the concentration of 50 nM and Lipofectamine®
RNAiMAX transfection reagent (Life Technologies). Cells were incubated
for another 48 h for RPTPβ/ζ and 72 h for XO in serum-containingmedium and serum starved before further experiments. Double-
stranded negative control siRNA was used in all experiments.
Assay of intracellular ROS production
ROS were assayed using the ROS-sensitive ﬂuorescent dye
carboxy-H2DCFDA, as previously described (Hatziapostolou et al.,
2006). Cells were seeded in 12-well plates at a concentration of
2 × 105 cells/well. Twenty four hours after seeding, LNCaP and PC3
cells were directly assayed for carboxy-DCF ﬂuorescence, as
described below, while HUVEC, M059K and CHO cells were serum-
starved and then incubated in serum-free medium containing
0.25% BSA and PTN for the indicated periods of time. When used,
antioxidants were added into the cell culture medium 30 min prior
to PTN stimulation. At the end of the incubation period, cells were
washed with phosphate-buffered saline (PBS) pH 7.4, and then
incubated in the dark for 15 min in Ham's F-12 lacking phenol red,
containing 50 μM carboxy-H2DCFDA. Cells were released with
trypsin/EDTA and lysed. Soluble extracts were prepared by centrifu-
gation for removal of cell debris and ﬂuorescence intensity was
determined spectrophotometrically, using an excitation wavelength
of 485 nm and emission wave-length of 500 nm. Cell lysates were
analyzed for protein content using the Bradford method, and
carboxy-DCF ﬂuorescence was normalized for total protein content.
Statistical analysis
The signiﬁcance of variability between the results of each group and
its corresponding control was determined by unpaired t test. Each
experiment included triplicatemeasurements for each condition tested,
unless otherwise indicated. All results are expressed as mean ± s.e.m.
from at least three independent experiments.
Results
PTN increases carboxy-DCF ﬂuorescence in a concentration- and
time-dependent manner
Treatment of HUVEC with PTN at the concentration of 100 ng/ml
that causes maximal stimulation of HUVEC migration (Polykratis
et al., 2005) resulted in a time-dependent increase in carboxy-DCF
ﬂuorescence, which was maximal 10 min after PTN stimulation
(Fig. 1A). Treatment of cells with different concentrations of PTN
for 15 min resulted in a concentration-dependent increase in
carboxy-DCF ﬂuorescence (Fig. 1B).
Similarly to HUVEC, PTN increased carboxy-DCF ﬂuorescence in a
concentration- and time-dependent manner also in human prostate
cancer LNCaP cells (Supplementary Figure S1). We have previously
shown that down-regulation of endogenous PTN in human prostate
cancer LNCaP (Hatziapostolou et al., 2005) or PC3 (Tsirmoula et al.,
2012) cells results in decreased ability of the cells to migrate and form
colonies in soft agar in vitro, increased apoptosis and decreased growth
in immunocompromised rats in vivo. In the present study, we used the
same cells stably expressing antisense PTN and investigated whether
endogenous PTN levels correlated with intracellular carboxy-DCF
ﬂuorescence. As shown in Fig. 2, intracellular carboxy-DCF ﬂuorescence
wasdecreased in both LNCaP and PC3 cellswith decreased expression of
endogenous PTN. In cells transfected with the appropriate control
vector, carboxy-DCF ﬂuorescence was similar to those in the
corresponding non-transfected cells.
RPTPβ/ζ is involved in PTN-induced elevation of carboxy-DCF ﬂuorescence
Since RPTPβ/ζ is one of themain PTN receptors, we studiedwhether
RPTPβ/ζ is involved in PTN-induced carboxy-DCF ﬂuorescence
elevation. Treatment of HUVEC with the protein tyrosine phosphatase
Fig. 1. PTN increases carboxy-DCF ﬂuorescence in a dose- and time-dependent manner.
Serum starved HUVEC were stimulated with 100 ng/ml PTN for different time points
(A) or with different concentrations of PTN for 15 min (B). In all cases, the ratio
carboxy-DCF ﬂuorescence/mg of total protein was calculated for each sample. Results
are expressed as mean ± s.e.m. of the percent change of carboxy-DCF ﬂuorescence per
mg of total protein in PTN-stimulated cells compared with the untreated cells (set as de-
fault = 100). Asterisks denote a statistically signiﬁcant difference from untreated cells.
***P b 0.001.
Fig. 2. Levels of endogenous PTN correlate with intracellular carboxy-DCF ﬂuorescence.
LNCaP (A) and PC3 (B) cells with decreased expression of endogenous PTN were used to
measure intracellular carboxy-DCF ﬂuorescence. Results are expressed as mean ± s.e.m.
of the percent change of carboxy-DCF ﬂuorescence per mg of total protein compared
with the corresponding non-transfected cells (set as default = 100). LNCaP, non-
transfected LNCaP cells; PC-LNCaP, cells transfected with the plasmid containing only
the neomycin resistance gene; AS-LNCaP, cells transfected with the plasmid containing
antisense PTN; PC3, non-transfected PC3 cells; PC-PC3, cells transfected with the plasmid
containing only the neomycin resistance gene; AS-PC3, cells transfected with the plasmid
containing antisense PTN.
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PTN resulted in complete elimination of PTN-induced carboxy-DCF
ﬂuorescence elevation (Fig. 3A), similarly to its effect on PTN-induced
cell migration (Polykratis et al., 2005). Since sodium orthovanadate is
a non-speciﬁc tyrosine phosphatase inhibitor, we then speciﬁcally
down-regulated the expression of RPTPβ/ζ by siRNA, as previously
described (Mikelis et al., 2009; Polykratis et al., 2005). Down-
regulation of RPTPβ/ζ resulted in complete inhibition of PTN-induced
carboxy-DCF ﬂuorescence elevation (Fig. 3B), verifying involvement of
RPTPβ/ζ in this effect. Similarly to HUVEC, RPTPβ/ζ seems to be involved
in PTN-induced carboxy-DCF ﬂuorescence elevation in LNCaP cells
(Supplementary Figure S2).
Integrin ανβ3 is involved in PTN-induced elevation of carboxy-DCF
ﬂuorescence
We have previously shown that ανβ3 integrin is forming a cell
surface functional complex with RPTPβ/ζ and is also required for PTN-
induced endothelial cell migration (Mikelis et al., 2009). Since we
know that PTN interacts with the speciﬁcity loop of the β3 integrin
extracellular domain (Mikelis et al., 2009), we tested the effect of a
synthetic peptide that corresponds to aminoacids 177CYDMKTTC184 of
the speciﬁcity loop (B3 peptide) and inhibits PTN-induced cell
migration (Mikelis et al., 2009) on PTN-induced carboxy-DCFﬂuorescence elevation. Pre-treatment of HUVEC with B3 peptide prior
to PTN stimulation completely abolished PTN-induced carboxy-DCF
ﬂuorescence elevation. A scrambled B3 peptide at the same concentra-
tion had no effect (Fig. 4A).
In order to further evaluate the role of ανβ3 on PTN-induced
carboxy-DCF ﬂuorescence elevation, we used mock-transfected CHO
cells that express αν but are negative for β3, as well as CHO cells over-
expressing wild-type β3 or mutant β3Y773F/Y785F (Mikelis et al.,
2009). PTN increased carboxy-DCF ﬂuorescence in CHO cells expressing
wild-type β3, but slightly decreased carboxy-DCF ﬂuorescence in CHO
cells that do not express β3 or express the mutant β3 subunit (Fig. 4B),
similarly to what has been previously observed for cell migration
(Mikelis et al., 2009).
Finally, we tested the effect of PTN on carboxy-DCF ﬂuorescence in
human glioma M059K cells that do not express cell surface ανβ3
(Mikelis et al., 2009). PTN caused a slight decrease in carboxy-DCF
ﬂuorescence in these cells (Fig. 4C), similarly to its effect on cell
migration (Mikelis et al., 2009).
PTN-induced elevation of carboxy-DCF ﬂuorescence lays
down-stream of c-src, PI3K and ERK1/2 activation
It is known that c-src, PI3K and ERK1/2 kinases participate in the PTN
signaling pathway that involves RPTPβ/ζ and ανβ3, and play a role in
PTN-induced cell migration (Koutsioumpa et al., 2013; Mikelis et al.,
Fig. 3. RPTPβ/ζ is involved in PTN-induced elevation of carboxy-DCF ﬂuorescence. Serum
starved HUVEC were pre-incubated with the tyrosine phosphatase inhibitor sodium
orthovanadate (20 nM) (A) or siRNA for RPTPβ/ζ (B) and then stimulated with PTN
(100 ng/ml). Results are expressed as mean ± s.e.m. of the percent change of carboxy-
DCF ﬂuorescence per mg of total protein in PTN-stimulated cells compared with the cor-
responding untreated cells (set as default = 100). s.o.: cells pre-treated with sodium
orthovanadate; siRPTPβ/ζ: cells transfected with siRNA for RPTPβ/ζ; siNegative: cells
transfected with a negative control siRNA; untransf: untransfected cells.
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possible role of these signaling molecules in PTN-induced carboxy-
DCF ﬂuorescence elevation. Pretreatment of HUVEC with the c-src
inhibitor PP1, the PI3K inhibitor wortmannin and the ERK1/2 activation
inhibitor U0126 at concentrations that inhibit PTN-induced cell
migration (Mikelis et al., 2009; Polykratis et al., 2005), completely
inhibited the effect of PTN on carboxy-DCF ﬂuorescence (Fig. 5).Xanthine oxidase mediates the PTN-induced elevation of carboxy-DCF
ﬂuorescence
Pre-treatment of HUVEC with catalase abolished PTN-induced
carboxy-DCFﬂuorescence elevation, suggesting that hydrogen peroxide
may be involved (Fig. 6A). To evaluate the enzymatic origin of ROS
generation in response to PTN, we used the NADPH oxidase inhibitors
AEBSF, apocynin and VAS2870, and the XO inhibitors allopurinol
and febuxostat. Treatment of HUVEC with allopurinol or febuxostat
prior to stimulation with PTN completely abolished PTN-induced
carboxy-DCF ﬂuorescence elevation, while the NADPH inhibitors gave
differential effects. Apocynin completely abolished, while AEBSF and
VAS2780 did not signiﬁcantly affect PTN-induced carboxy-DCF ﬂuores-
cence elevation (Fig. 6A). These data suggest that XO but not NADPH
oxidase is involved in PTN-stimulated ROS production in HUVEC.
Down-regulation of endogenous XO expression by siRNA abolished
PTN-induced carboxy-DCF ﬂuorescence elevation, verifying XO involve-
ment (Fig. 6B).We next studied whether PTN-induced endothelial cell migration
was mediated by elevation of intracellular ROS levels. Pre-treatment of
HUVECwith catalase inhibited PTN-induced HUVECmigration, suggest-
ing that ROS are required for the stimulatory effect of PTN on cell migra-
tion. Pre-treatment of HUVEC with allopurinol and febuxostat also
completely abolished PTN-induced HUVEC migration, suggesting that
XO is involved in PTN-induced migration. The different NADPH
inhibitors used gave differential effects. Apocynin completely abolished
PTN-induced HUVEC migration. VAS2780 had a small inhibitory effect
on HUVEC migration by itself, but did not inhibit the stimulatory effect
of PTN. Finally, in the presence of AEBSF, PTN signiﬁcantly decreased
HUVEC migration (Fig. 6C). Down-regulation of endogenous XO
expression by siRNA abolished PTN-induced endothelial cell migration,
verifying XO involvement (Fig. 6D).
Discussion
Several previous studies have shown generation of ROS in a variety
of cells upon stimulation by different growth factors and involvement
of ROS in growth factor actions (Hatziapostolou et al., 2006; Lange
et al., 2009; Polytarchou and Papadimitriou, 2004, 2005; Ushio-Fukai,
2007). In the present study, we show for the ﬁrst time that PTN also
increases ROS production in a concentration- and time-dependent
manner in human endothelial and prostate cancer cells. Although
carboxy-DCF ﬂuorescence can be increased by several oxidants
(Kalyanaraman et al., 2012), the observation that catalase abolished
PTN-induced carboxy-DCFDA oxidation, suggests involvement of
hydrogen peroxide. The enzyme responsible for PTN-induced ROS
production seems to be XO, based on the observation that XO pharma-
cological inhibitors and down-regulation of endogenous XO abolished
the stimulatory effect of PTN on ROS production. The lack of effect of
the NADPH oxidase inhibitors AEBSF and VAS22780 on PTN-induced
ROS production suggests that NADPH oxidase is not involved,
while the inhibitory effect of apocynin could be due to its scavenging
properties for hydrogen peroxide (Heumüller et al., 2008).
XO is a major source of ROS and has been linked to the pathogenesis
of several inﬂammatory diseases, such as atherosclerosis (Nomura et al.,
2014; Schröder et al., 2006), chronic obstructive pulmonary disease
(Komaki et al., 2005), interstitial ﬁbrosis in chronic kidney disease
(Omori et al., 2012), inﬂammation in Type I diabetes (Romagnoli et al.,
2010) and vascular inﬂammation (Sabán-Ruiz et al., 2013). PTN is also
involved in inﬂammatory pathologies (Pantazaka and Papadimitriou,
2012; Papadimitriou et al., 2009; Silver et al., 2012; Yokoi et al., 2012;
Zhang et al., 2013) and activation of XOmight be one of themechanisms
of its pro-inﬂammatory effects. In favor of this notion are data showing
that interferon gamma (IFNγ), which is a known inducer of XO (Dupont
et al., 1992), up-regulates PTN expression in capillaries of human
atherosclerotic plaques through JAKs/STATs downstream effectors (Li
et al., 2010). Since XO is involved in the pathogenesis of atherosclerosis
(Nomura et al., 2014) and its activation is also mediated by JAKs/STATs
(Wang et al., 2008), one can speculate that PTNmediates the stimulato-
ry effect of IFNγ on XO activation, similarly to its role as a mediator of
the stimulatory effects of hydrogen peroxide (Polytarchou et al.,
2005), nitric oxide (Polytarchou et al., 2009) and ﬁbroblast growth
factor-2 (Hatziapostolou et al., 2006). In the same line, hypoxia
stimulates both PTN expression (Antoine et al., 2005) and XO activation
(Wang et al., 2008), suggesting that hypoxia-induced XO activation
might be also mediated by PTN over-expression.
Involvement of ROS in the stimulatory effects of growth factors has
been previously shown, with NADPH oxidase considered as the main
source of ROS (Sies, 2014). There is also one study showing involvement
of endogenous XO in VEGF-induced actions, such as endothelial cell
survival (Kou et al., 2008), suggesting that multiple sources of ROS
may orchestrate the various effects of growth factors. In the present
study we show that XO mediates the stimulatory effect of PTN on cell
migration and could be hypothesized that XO might also mediate the
Fig. 4. Integrinανβ3 is involved in PTN-induced elevation of carboxy-DCF ﬂuorescence. (A) Serum starved HUVECwere incubatedwith PTN for 15min in the presence or absence of 1 μg/
ml peptide B3 (corresponds to the extracellular loop ofβ3 known to be responsible for the interactionwith PTN), or a scrambled B3peptide. (B)Mock-transfected CHO cells negative for β3
(vector), as well as CHO cells over-expressing wild-type β3 (wtβ3) or mutant β3Y773F/Y785F (mutβ3), were treatedwith PTN for 15min. (C) Serum starvedM059K cells (do not express
ανβ3 and do not migrate in response to PTN) were incubated with 100 ng/ml PTN for 15 min. In all cases, the ratio carboxy-DCF ﬂuorescence/mg of total protein was calculated for each
sample. Results are expressed as mean ± s.e.m. of the percent change of carboxy-DCF ﬂuorescence per mg of total protein in PTN-stimulated cells compared with the corresponding
untreated cells (set as default = 100).
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human prostate cancer cells that express low PTN levels have increased
rates of apoptosis (Tsirmoula et al., 2012), decreased migration
(Hatziapostolou et al., 2005; Tsirmoula et al., 2012) and decreasedFig. 5. PTN-induced carboxy-DCF ﬂuorescence elevation was inhibited by inhibition of c-
src and PI3-K or inhibition of ERK1/2 activation. Serum starved HUVEC were pre-incubat-
ed for 30 min with the c-src inhibitor PP1 (20 nM), the PI3K inhibitor wortmannin
(100 nM) or the ERK1/2 activation inhibitor U0126 (20 nM) and then stimulated with
PTN for 15 min. The ratio carboxy-DCF ﬂuorescence/mg of total protein was calculated
for each sample. Results are expressed as mean ± s.e.m. of the percent change of
carboxy-DCF ﬂuorescence per mg of total protein in PTN-stimulated cells compared
with the untreated cells (set as default = 100).growth and metastases in vivo (Tsirmoula et al., 2012), and based on
the present study, these same cells have lower levels of ROS compared
with the corresponding cells expressing normal PTN levels. These data
are also in linewith data showing that XO levels are elevated in patients
with prostate cancer (Samra et al., 2011), as well as several other types
of cancer, such as breast, lung and bladder cancer, non-Hodgkin
lymphoma and acute lymphoblastic lymphoma (Samra et al., 2011;
Güleç et al., 2003). On the other hand, decreased XO activity has been
found in hepatomas (Prajda and Weber, 1975; Prajda et al., 1976) and
gastric cancer (Linder et al., 2006), which could be explained by the
hypothesis that XO expression may be cancer type-speciﬁc. XO has
been also shown to stabilize hypoxia-inducible factor-1alpha (HIF-1α)
under hypoxic conditions in glioma cells (Griguer et al., 2006), which
is also in favor of a regulatory role of XO in cancer and angiogenesis.
Hydrogen peroxide activates HIF-1α in cancer and/or stroma cells,
contributing to cancer metabolism and metastasis (Lisanti et al.,
2011), although up to date the enzymatic sources of cancer-associated
hydrogen peroxide remain poorly studied. Taking into account that
XO has been linked to several inﬂammatory conditions, as discussed
above, it would be interesting to further investigate its role in cancer.
By using several pharmacological and genetic approaches, we found
that the cell surface functional complex of RPTPβ/ζ/ανβ3 that is
required for PTN-induced cell migration (Mikelis et al., 2009), is also
involved in PTN-induced ROS production. Moreover, the enzymatic
source of ROS lays down-stream of c-Src, PI3K and ERK1/2, which are
also involved in PTN-induced cell migration downstream of RPTPβ/ζ
(Polykratis et al., 2005). Although ROS are known to act as growth factor
downstream signaling molecules that inhibit protein tyrosine
Fig. 6. ROS scavenging and XO inhibition or down-regulation completely abolished both PTN-induced carboxy-DCF ﬂuorescence elevation and cell migration. (A) Serum starved HUVEC
were stimulated with 100 ng/ml PTN for 10 min in the presence or absence of catalase (750 units/ml), apocynin (100 μM), AEBSF (200 μΜ), VAS2870 (10 μΜ), allopurinol (1 mM) and
febuxostat (10 μΜ). Results are expressed asmean±s.e.m. of thepercent change of carboxy-DCF ﬂuorescence permg of total protein in PTN-stimulated cells comparedwith theuntreated
cells (set as default = 100). (B) Up: HUVEC lysates after treatment with siRNA for XOwere analyzed byWestern blot analysis for the presence of the protein. siNegative: cells transfected
with a negative control siRNA; siXO: cells transfected with siRNA for XO. Down: Serum starved HUVEC were stimulated with 100 ng/ml PTN for 10 min. Results shown are from a
representative experiment and are expressed as the percent change of carboxy-DCF ﬂuorescence permg of total protein in PTN-stimulated cells comparedwith the corresponding untreated
cells (set as default= 100). (C) Serum starved HUVECwere stimulatedwith 100 ng/ml PTN for 4 h in the presence or absence of the tested agents asmentioned above. Results are expressed
as mean± s.e.m. of the percentmigration of PTN-treated compared with the untreated cells (set as default = 100). (D) Serum starved HUVECwere stimulated with 100 ng/ml PTN for 4 h.
Results are expressed as mean ± s.e.m. of the percent migration of PTN-treated compared with the corresponding untreated cells (set as default = 100). Asterisks in A and C denote a
statistically signiﬁcant difference. **P b 0.01, ***P b 0.001.
79S. Tsirmoula et al. / Microvascular Research 98 (2015) 74–81phosphatases (Ray et al., 2012) and are produced in response to
integrin activation either independently or in cooperation with
growth factor receptors (Goitre et al., 2012), to the best of our
knowledge this is the ﬁrst study that shows implication of a receptor
tyrosine phosphatase, RPTPβ/ζ, on ROS production. Moreover, al-
though not many data are available on the signaling molecules af-
fecting XO activation in endothelial or other types of cells, ERK1/2
have been previously shown to lay upstream and to induce XO enzy-
matic activity in response to mechanical stress in rat pulmonarymicrovascular endothelial cells (Abdulnour et al., 2006), in line with
our observation.
Increased ROS levels as a result of PTN stimulation of endothelial
cells correlate with increased cell migration. Similarly, higher PTN
expression correlates with higher endogenous ROS levels (this study)
and increased migration (Hatziapostolou et al., 2005; Tsirmoula et al.,
2012) in human prostate cancer cells. The role of XO in PTN-induced
endothelial cell migration is supported by the data showing that allopu-
rinol and febuxostat, similarly to ROS scavenging and down-regulation
80 S. Tsirmoula et al. / Microvascular Research 98 (2015) 74–81of endogenous XO expression, completely abolished PTN-induced cell
migration. The NADPH inhibitors gave conﬂicting results: apocynin
caused complete inhibition of cell migration, while VAS2780 had no
effect, similarly to their corresponding effects on ROS levels. On the
other hand, AEBSF not only inhibited the stimulatory effect of PTN, but
in its presence, PTN signiﬁcantly inhibited cell migration. Besides
inhibiting NADPH oxidase, AEBSF can also act as a serine protease
inhibitor (Wind et al., 2010). It is not known whether this is the reason
for the decrease in cell migration caused by PTN in the presence of
AEBSF, but it may be a possibility since PTN has been shown to enhance
plasminogen activator activity in bovine aortic endothelial cells (Kojima
et al., 1995). Considering the basic role of plasmin in endothelial cell mi-
gration (Heissig et al., 2012), it could be hypothesized that PTNexerts its
stimulatory effect on cell migration by activating serine proteases.
Conclusions
XO-mediated ROS production through the cellmembrane functional
complex of RPTPβ/ζ and ανβ3 and activation of c-src, PI3-K and ERK1/2
kinases, is required for PTN-induced cell migration. Further studies are
in progress to elucidate the role of XO and ROS in PTN signaling and
functions in endothelial and other types of cells.
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